Browsing: Medication & Drugs

Singapore’s HSA New Drugs and Indications Approval – Jan 2022

By Sian LinFebruary 24, 20220

HSA approves the first JAK inhibitor for moderate-to-severe atopic dermatitis: baricitinib (Olumiant)

By KayeFebruary 17, 20220

Current Oral Drugs Available for COVID-19 Treatment

By Kopal SinghalFebruary 8, 20220

Although majority of COVID-19 cases present as mild to moderate disease which can be managed at home simply with over-the-counter…

Eptinezumab (Vyepti) for preventive treatment of both episodic and chronic migraine

By EmmaFebruary 2, 20220

Singapore’s HSA New Drugs and Indications Approval – Dec 2021

By Sian LinJanuary 25, 20220

Molnupiravir for COVID-19? 5 Things You Need To Know About This Oral Drug

By Tony ZhangJanuary 25, 20220

The COVID-19 pandemic is an ongoing global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of 21…

The growing biologic armamentarium of plaque psoriasis treatment: A review of risankizumab (Skyrizi)

By KayeJanuary 20, 20220

Singapore’s HSA ADR News Bulletin – Dec 2021

By Alyssa YapJanuary 18, 20220

Singapore’s HSA New Drugs and Indications Approval – Nov 2021

By Sian LinDecember 30, 20210

Singapore’s HSA approves vericiguat (Verquvo) for use in high-risk heart failure patients with reduced ejection fraction

By KayeDecember 16, 20210

Copyright © Medical Channel Asia 2024. All rights reserved.
The contents on Medical Channel Asia are for general educational purposes only.
It is not intended to be a substitute for professional medical advice, treatment, or diagnosis.
See additional information.

What's Hot

5 Strategies for Doctors to Attract More Patients

The Placebo Effect of Vitamins: Belief vs Reality

Does Freezing Bread Really Lower Its Glycaemic Index?

Browsing: Medication & Drugs

Singapore’s HSA New Drugs and Indications Approval – Jan 2022

HSA approves the first JAK inhibitor for moderate-to-severe atopic dermatitis: baricitinib (Olumiant)

Current Oral Drugs Available for COVID-19 Treatment

Eptinezumab (Vyepti) for preventive treatment of both episodic and chronic migraine

Singapore’s HSA New Drugs and Indications Approval – Dec 2021

Molnupiravir for COVID-19? 5 Things You Need To Know About This Oral Drug

The growing biologic armamentarium of plaque psoriasis treatment: A review of risankizumab (Skyrizi)

Singapore’s HSA ADR News Bulletin – Dec 2021

Singapore’s HSA New Drugs and Indications Approval – Nov 2021

Singapore’s HSA approves vericiguat (Verquvo) for use in high-risk heart failure patients with reduced ejection fraction

5 Strategies for Doctors to Attract More Patients

The Placebo Effect of Vitamins: Belief vs Reality

Does Freezing Bread Really Lower Its Glycaemic Index?

How Telemedicine is Transforming The Way Singaporeans Manage Diabetes

Subscribe to Updates

What's Hot

Browsing: Medication & Drugs

Subscribe to Updates